This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
Pressure BioSciences, Inc. (OTCQB: PBIO) to Present at the FSXinterlinked Investment Conference, the premier investment conference organization in the United States.
(PRWEB) July 15, 2014
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the FSXinterlinked Investment Conference being held from July 30th to August 2nd, 2014 at the Four Seasons, Westlake Village, CA.
In addition to his presentation, Mr. Schumacher will be available during the conference for one-on-one meetings with individual investors, investment funds, investment bankers, and other interested parties.
About FSXinterlinked Investment Conference
FSXinterlinked is the premier investment conference organization in the United States. Founded in 1983, FSXinterlinked is a national organization comprised of independent broker/dealer firms and private equity fund managers. With quarterly investment conferences hosted throughout the U.S., FSXinterlinked creates a forum for emerging growth companies seeking capital to present to a nationwide network of financial investment professionals. Through the FSXinterlinked partnership, companies and investors can easily connect, build relationships, and close deals faster.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/07/prweb12017596.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.